Pfizer now has the data it needs to apply for COVID vaccine approval
- Written by Kylie Quinn, Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
ShutterstockOn Wednesday, Pfizer and BioNTech announced their mRNA vaccine has demonstrated a remarkable 95% efficacy in the “final efficacy analysis” of its phase 3 trial.
The news comes hot on the heels of Pfizer/BioNTech’s interim analysis last week, which pointed to greater than 90% efficacy, and Moderna’s announcement o...





